Silvia Muller de Moura Sarmento

Dr. Silvia Muller de Moura Sarmento


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Diseases
Verified
Journal Article
Open access
PDF file
Carolina Pereira de OliveiraCarolina Pereira de Oliveira
Carolina Pereira de Oliveira
LSLaura Smolski dos Santos
Laura Smolski dos Santos
GSGênifer Schreiner
Gênifer Schreiner
CPCamila Berny Pereira
Camila Berny Pereira
SSSilvia Muller de Moura Sarmento
Silvia Muller de Moura Sarmento
VMVanusa Manfredini
Vanusa Manfredini
Objective: This study aimed to analyze the epidemiological, hematological, and oxidative stress profile of truck drivers. Method: It involved 63 drivers from the western border of a state in southern Brazil who completed a questionnaire, had vital signs and anthropometric evaluations, and provided blood samples. Hematological parameters, leukocytes, and oxidative damage to proteins and lipids were analyzed. Results: A high prevalence of overweight and obesity was found among the drivers, with an increased risk of cardiovascular issues and hypertension. Obese drivers had higher monocyte counts, while those with normal weight had increased protein carbonylation levels. Conclusions: It is crucial to implement health interventions to prevent chronic diseases in truck drivers, given their high exposure to risk factors.

23 October 2025 in Livers
Verified
Journal Article
Open access
PDF file
SSSilvia Muller de Moura Sarmento
Silvia Muller de Moura Sarmento
GSGênifer Schreiner
Gênifer Schreiner
LSLaura Smolski dos Santos
Laura Smolski dos Santos
CPCamila Berny Pereira
Camila Berny Pereira
ESElizandra Gomes Schmitt
Elizandra Gomes Schmitt
VMVanusa Manfredini
Vanusa Manfredini
Background/Objectives: Vitamin D is recognized as a key modulator of metabolic diseases, including metabolic-dysfunction-associated steatotic liver disease (MASLD), in which its deficiency contributes to both disease onset and progression. Despite the widespread and often prolonged use of vitamin D supplementation, optimal serum levels in individuals with MASLD remain unclear and warrant further investigation. Methods: In this study, hepatic steatosis was induced in male and female Wistar rats over a 45-day period. The animals were then divided into five groups (control, 2500, 7000, 14,000, and 21,000 IU/kg/week of cholecalciferol). After four weeks of treatment, the animals were euthanized, and blood samples were collected for biochemical, hormonal, inflammatory, oxidative stress analyses and liver architecture evaluation. Results: High-dose vitamin D supplementation in rats with MASLD induced dose-dependent metabolic, inflammatory, and oxidative changes, with some sex-specific differences. Urea and alanine aminotransferase levels increased at higher doses in both sexes, suggesting potential nephrotoxic and hepatotoxic effects, while creatinine and aspartate aminotransferase remained stable. Adiponectin levels decreased consistently, and leptin levels rose across all doses, indicating a shift toward a pro-adipogenic profile. Pro-inflammatory molecules (IL-1β, IL-6, IL-8, TNF, C-reactive protein) increased progressively with dose, while IL-10 followed a U-shaped curve. Oxidative stress markers showed elevated protein carbonylation only at the highest dose, a slight reduction in TBARS, and a peak in total antioxidant status at 7000 IU/kg/week. Conclusions: High-dose vitamin D triggers antioxidant responses but drives harmful inflammatory and metabolic shifts in MASLD.

6 January 2026 in COVID
Verified
Journal Article
Open access
PDF file
LSLaura Smolski dos Santos
Laura Smolski dos Santos
GSGênifer Schreiner
Gênifer Schreiner
ESElizandra Schmitt
Elizandra Schmitt
MSMariana Larré da Silveira
Mariana Larré da Silveira
CPCamila Berny Pereira
Camila Berny Pereira
VMVanusa Manfredini
Vanusa Manfredini
Background: In 2019, a new virus caused by SARS-CoV-2, called COVID-19, spread throughout the world, causing a pandemic state. As the pandemic progressed and cases continued to increase, safe vaccines were developed for the entire population. In Brazil, AstraZeneca® (ChAdOx1-S) and Pfizer® (BNT162b2) vaccines were among those administered to the population. Objectives: The objective of this study was to analyze whether immunoglobulin G (IgG) is produced for COVID-19 in individuals immunized with two doses of AstraZeneca (ChAdOx1-S) and Pfizer (BNT162b2) vaccines and to evaluate several parameters in order to understand how our bodies respond to this immunization. Methods: The study involved the participation of 120 individuals: 49 in the control group, 44 vaccinated with the AstraZeneca vaccine, and 27 the vaccinated with Pfizer vaccine. Results: Hematological, biochemical, inflammatory, and oxidant/antioxidant parameters and the production of IgG antibodies were analyzed. An increase in some inflammatory parameters was observed in vaccinated individuals, which may have been caused by an immune reaction after vaccination. In terms of hematological parameters, the changes caused by vaccination appear to be transient and quickly resolved after immunization. In terms of biochemical parameters, an increase in IgG antibodies was observed in the group vaccinated with the Pfizer® vaccine; however, the AstraZeneca® and control groups also produced IgG, although to a lesser extent. In terms of the remaining parameters, there was little change after vaccination. Regarding the levels of oxidants/antioxidants, it was observed that there was a compensation by antioxidants due to the increase in oxidant parameters, which may act as corrective mechanism. Conclusions: Both the AstraZeneca® and Pfizer® vaccines induced anti-SARS-CoV-2 IgG production, accompanied by inflammatory, hematological, and oxidative changes.